Concepedia

Author

Michael J. Dowzicky

Pfizer (United States)

Also Known As

ASCOLI, Valeria, Dowzicky M, Dowzicky, M.J., M Dowzicky, M J Dowzicky, M. Dowzicky, M. J. Dowzicky, M.J Dowzicky, M.J. Dowzicky, Michael Dowzicky

140

Publications

3.5K

Citations

36

H-Index

43

Concepts

All Affiliations

Pfizer (United States)South CollegeTufts UniversityJMI Laboratories
MJ

About

Michael J. Dowzicky is an author at Pfizer (United States) specializing in medicine, clinical microbiology, and antimicrobial resistance.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

27

37

1.9K

2

Health Sciences

11

11

640

3

Public Health

2

2

116

4

Engineering

1

1

11

5

Allergy

1

1

81

Michael J. Dowzicky

×

66

Publications

3.4K

Citations

35

H-Index

YearCitations

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)

Daryl J. Hoban, Samuel K. Bouchillon, Brian Johnson,

Diagnostic Microbiology and Infectious Disease

2005

205

Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline

R. R. Reinert, Donald E. Low, F. Rossi,

Journal of Antimicrobial Chemotherapy

2007

188

Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial

Anna Giammanco, Cinzia Calà, Teresa Fasciana,

mSphere

2017

168

Determining incidence of extended spectrum β-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001–2002

S. Bouchillon, Brian Johnson, D. Hoban,

International Journal of Antimicrobial Agents

2004

141

Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit

Hélio S. Sader, Ronald N. Jones, Michael J. Dowzicky,

Diagnostic Microbiology and Infectious Disease

2005

113

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents

Hélio S. Sader, Ronald N. Jones, Matthew G. Stilwell,

Diagnostic Microbiology and Infectious Disease

2005

113

Antimicrobial Susceptibility Among Gram-Negative Isolates Collected From Intensive Care Units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa Between 2004 and 2009 as Part of the Tigecycline Evaluation and Surveillance Trial

Xavier Bertrand, Michael J. Dowzicky

Clinical Therapeutics

2011

110

Antimicrobial Susceptibility among Pathogens Collected from Hospitalized Patients in the United States and In Vitro Activity of Tigecycline, a New Glycylcycline Antimicrobial

Ken B. Waites, Lynn B. Duffy, Michael J. Dowzicky

Antimicrobial Agents and Chemotherapy

2006

91

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)

Samuel K. Bouchillon, Daryl J. Hoban, Brian Johnson,

Diagnostic Microbiology and Infectious Disease

2005

88

Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004–2009

Stephen Hawser, Samuel K. Bouchillon, Daryl J. Hoban,

International Journal of Antimicrobial Agents

2011

84

Page 1